S. Peters, U. Dafni, J. Federer-Gsponer, M. Ballinger, Maximilian Christopeit, G. Dimopoulou, M. Perol, M. Provencio Pulla, M. Reck, E.F. Smit, Z. Tsourti, S. Morris, R.A. Stahel
The main objective of the i-TIMES study is to investigate the effect of the timing of immune checkpoint inhibitor (ICI) early vs late in the day, on overall survival (OS) for patients (pts) with lung cancer and secondarily in other solid tumors using data from randomized clinical trials (RCTs).